Results from the SAINT II (Stroke Acute Ischemic NXY-059 Treatment) trial, announced today by AstraZeneca, showed that the investigational drug NXY-059 did not meet its primary outcome of a statistically significant reduction in stroke-related disability, as assessed by the modified Rankin Scale (mRS) (p=0.33, odds ratio 0.94) compared to placebo.
Poor adherence to medication is a recognized medical problem, costing an estimated $100 billion a year in the United States.(i) New data show that while there is a steady decline in adherence to medications for ulcerative colitis (UC), drug formulation and the number of pills taken each day do not affect long-term adherence. The data were presented today at the annual scientific meeting of the American College of Gastroenterology by University of Chicago researcher Sunanda Kane, M.D.
Merck & Co., Inc. announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) voted unanimously to recommend that adults 60 years of age and older be vaccinated with ZOSTAVAX? [Zoster Vaccine Live (Oka/Merck)] to help prevent shingles (herpes zoster), a frequently painful disease marked by a blistering rash.
The gastrointestinal medicine Zelnorm? (tegaserod maleate) has demonstrated potential benefits in helping patients with the multiple symptoms of a common digestive disorder called dysmotility-type dyspepsia[1], according to new Phase III data presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting.
Abbott announced results from a study showing HUMIRA? (adalimumab) induced significantly higher rates of clinical remission compared to placebo in patients with moderately to severely active Crohn’s disease who lost response to, or were intolerant to, infliximab therapy. The data is being presented simultaneously at the American College of Gastroenterology (ACG) annual meeting in Las Vegas and the United European Gastroenterology Week (UEGW) in Berlin.
The Food and Drug Administration (FDA) announced the approval of Omnaris (ciclesonide) nasal spray, a new drug for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis, commonly known as hay fever, in adults and children 12 years of age and older.
Conventional treatment for genital warts, which are caused by the human papilloma virus (HPV), typically focuses on the visible lesions, leaving the possibility that latent infection could persist. That can result in transmission of the virus to sexual partners, and the infection could progress to cervical cancer.
AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL? (quetiapine fumarate) for the treatment of patients with depressive episodes associated with bipolar disorder. SEROQUEL already is approved for the treatment of acute manic episodes associated with bipolar I disorder and for the treatment of schizophrenia. SEROQUEL is now the first and only single medication approved by the FDA to treat both depressive and manic episodes associated with bipolar disorder.
AVI BioPharma, Inc. (Nasdaq: AVII), presented data and analysis from four NeuGene? antisense clinical studies at the second annual meeting of the Oligonucleotide Therapeutics Society at Rockefeller University in New York. The studies showed that AVI-4557 inhibited the metabolic enzyme cytochrome P450 (CYP), a liver enzyme responsible for the metabolism or breakdown of approximately half of currently marketed drugs.
Array BioPharma Inc. (Nasdaq: ARRY) announced that its first-in-class MEK inhibitor for the treatment of inflammatory diseases, ARRY-438162, has met its primary objectives in a single ascending dose clinical study involving 20 healthy volunteers. These results were presented by Array?s President and Chief Scientific Officer, Kevin Koch, Ph.D., at the 14th International Inflammation Research Association Conference in Cambridge, Maryland.